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Abstract: This paper reviews the current data on the use of the first approved intravenous 
  ibuprofen product for the management of post-operative pain and fever in the United States. 
The management of acute and post-operative pain and fever with nonsteroidal anti-inflammatory 
agents (NSAIDs) is well documented. A search in Medline and International Pharmaceutical 
Abstracts of articles until the end of November 2009 and references of all citations were con-
ducted. Available manufacturer data on file were also analyzed for this report. Several randomized 
controlled studies have demonstrated the opioid-sparing and analgesic effects of 400 and 800 mg 
doses of intravenous ibuprofen in a series of post-operative patient populations. Two recent studies 
have also noted the improvement in fever curves in critically ill and burn patients. These data, 
along with pharmacokinetic and pharmacologic properties, are explored in this review, which 
addresses the clinical utility of a parenteral NSAID in a hospitalized patient for post-operative 
pain management and fever reduction. Further data on intravenous ibuprofen are needed to define 
long-term utilization, management of acute pain, and use in special populations.
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Introduction
Acute pain is a significant problem for inpatients and can occur secondary to acute 
illness or disease processes, trauma, or operative procedures. In the post-operative 
period, 80% of individuals suffer from post-operative pain with almost all describing 
it as moderate to severe.1 Physiologically, pain serves to alert individuals to tissue 
damage and to prevent further harm. However, in the acute inpatient setting, it often 
serves no useful purpose. Pain activates the sympathetic nervous system, increasing 
blood pressure, cardiac workload and respiratory rate.2 It impairs recovery by reducing 
mobility and physical activity. Despite the use of medications to control pain, it often 
remains undertreated and is a problem in hospitals and long-term care facilities.
Opioid analgesics are a mainstay in the management post-operative and acute pain 
in the inpatient setting.3 However, their use is often limited by adverse effects including 
respiratory depression, sedation, allergic reactions, and gastrointestinal events. Opioids 
are useful in mitigating the sensation of pain, but provide no benefits to the underlying 
disease process. Adjunctive agents for pain including non-steroidal anti-inflammatory 
agents (NSAIDs) may be used in combination with opioids. Combination therapy may 
help mitigate the side effects of both agents by reducing the total dose required. The 





and resolution of pain. NSAIDs inhibit the production of 
cyclooxygenase (COX)-1 and COX-2 enzymes and prevent 
the sensitization of pain receptors at the site of injury. The 
American Pain Society advocates the use of combination 
therapy including NSAIDs, for optimal pain control.4 The 
World Health Organization (WHO) includes NSAIDs in 
step 1 of the analgesic ladder for the treatment of mild to 
moderate pain.5 They are also included as adjuncts in the 
treatment of persistent and moderate to severe pain in steps 
2 and 3, respectively.
Recent data on the safety of COX-2 selective agents and 
fraudulent data in previously published pain studies have 
created significant clinical questions for clinicians. NSAIDs, 
particular COX-2 selective agents, have received great criticism 
related to an increased risk of cardiovascular events, including 
acute myocardial infarction, stroke, and coronary heart disease 
death.6–8 As a result, many agents were removed from the 
market worldwide. Likewise, information on the publication of 
fraudulent data has led to the retraction of a significant number 
of papers on the safety and efficacy of both COX-2 selective 
agents and NSAIDs in the post-operative setting.9 These 
significant controversies create a need for additional research 
in the field and for new products and formulations.
The antipyretic effects of NSAIDs are also well docu-
mented, resulting from inhibition of COX-1 to block the 
conversion of arachidonic acid to prostaglandins such as 
PGE2 in the immune response pathway.10 Fever is common 
in hospitalized patients and can be a result of infection, 
thrombosis, autoimmune disorders, malignancies, drugs, or 
other unknown causes.11 Reduction of fever not only offers 
substantial benefit to a patient’s well-being but the metabolic 
compromise of sustained fever may potentiate risks associ-
ated with common co-morbidities encountered in hospital-
ized patients. Ibuprofen has been a primary agent of choice, 
along with acetaminophen, in the reduction of fever in both 
adults and children. Data have demonstrated equal efficacy 
between the two and offered pharmacokinetic advantages of 
ibuprofen in early onset and durable antipyretic effects after 
therapeutic concentrations have waned.12,13
Until recently, ketorolac (Toradol®; Roche Laboratories, 
Nutley, NJ, USA) was the only NSAID available in parenteral 
form in the United States (US), and while it possesses known 
antipyretic effects, it is most frequently used in the manage-
ment of acute and post-operative pain. Its use is limited by 
side effects that prohibit more than 5 days of therapy.14 Many 
practitioners also have the perception that it is more effective 
than oral ibuprofen.15 However, a review of studies examin-
ing both parenteral ketorolac and oral ibuprofen found that 
oral ibuprofen is as effective as ketorolac in the management 
of pain in emergency department patients. The authors also 
point out that the cost of oral ibuprofen is significantly less 
than parenteral ketorolac. Additional parenteral options 
are available outside the US where approved. Tenoxicam 
(Mobiflex®; Roche Laboratories, United Kingdom) is an 
intravenous NSAID available in the United Kingdom.16 
Parecoxib (Dynastat®; European Union) is the first COX-2 
inhibitor available for parenteral administration and is 
approved through much of Europe for short-term periopera-
tive pain control much in the same way ketorolac (Toradol®) 
is used in the US.17 Two formulations of injectable diclofenac 
are available (Dyloject®; Javelin Pharmaceuticals, United 
Kingdom and Voltarol®; Novartis, United Kingdom). Dyloj-
ect® is a novel injectable diclofenac formulation employing 
polyethylene glycol and benzyl alcohol as excipients, and is 
marketed in Europe and requires specific reconstitution slow 
infusion to minimize venous irritation.18 These products are 
not discussed further as a part of this review.
Oral ibuprofen is a commonly used NSAID with anti-
pyretic, anti-inflammatory, and analgesic properties. It is 
a mainstay in the treatment of acute pain and fever and 
is readily available over the counter. Mechanistically, it 
acts both centrally and peripherally to reduce pain and 
fever. However, the use of ibuprofen in the inpatient or 
post-operative setting has previously been limited by the 
lack of a commercially available parenteral formulation. 
The drug’s lipophilic properties have rendered production 
into an intravenous formulation difficult, but an intravenous 
form of ibuprofen (Caldolor®; Cumberland Pharmaceuticals, 
Nashville, TN, USA) has recently been approved for use in 
the US. Previously, ibuprofen was available in a parenteral 
form as a lysine salt (Neoprofen®) and an intravenous solu-
tion (Pedea®) only for treatment of patent ductus arteriosus in 
the neonatal population.19,20 Studies found that intravenous 
ibuprofen use improved pain control and reduced opioid use 
in the orthopedic and abdominal surgery setting as well as 
on fever reduction in the critically ill population. Its impact 
on pain management in the acute and post-operative settings, 
as well as long-term use remains undefined.
Methods
We conducted a Medline search for all articles published until 
the end of November 2009 using the MeSH terms “intrave-
nous” and “ibuprofen”. Additional searches of International 
Pharmaceutical Abstracts and EMBASE were conducted 
using the search terms “intravenous ibuprofen”. Articles 
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than pain management, including patent ductus arteriosus, 
and hypoxic   ischemic encephalopathy, ibuprofen lysine, 
Pedea®, and animal data, were excluded. Reference lists from 
retrieved articles were also searched for additional relevant 
citations. Meeting abstracts were searched for pertinent cita-
tions. Unpublished data were also obtained by special request 
from Cumberland Pharmaceuticals (Nashville, TN, USA).
Pharmacology
Mechanism of action
The mechanism of action and pharmacology of intravenous 
ibuprofen does not differ from the mechanism of oral ibu-
profen. It works through reversible inhibition of COX-1 and 
COX-2 enzymes to decrease the conversion of arachidonic 
acid into prostaglandin endoperoxides including thrombox-
ane and prostacyclin.21
The separation of functions of COX-1 and COX-2 is 
not straightforward, and a mixture of their activity is fre-
quently responsible for the therapeutic and adverse effects 
of NSAIDs, including ibuprofen.21,22 COX-2 is produced in 
response to tissue injury, growth factors, tumor promoters 
and cytokines.21 COX-1 is found in most cells and maintains 
many physiologic housekeeping functions. Inhibition of 
prostaglandin E2 (PGE2) is responsible for the anti-pyretic 
properties of NSAIDs. The pain-relieving properties of 
NSAIDs relate to the inhibition of PGE2 and its effects periph-
erally and centrally. COX-1 and COX-2 in the spinal cord 
are released in response to painful peripheral stimuli to form 
prostaglandins which sensitizes peripheral nerve endings. 
Inhibition desensitizes the painful response. Centrally, inhi-
bition of these enzymes in the spinal cord blunts the central 
sensitization and increase in excitability of spinal dorsal horn 
neurons seen in response to painful stimuli. Prostaglandins 
PGE2 and PGI2 are responsible for inflammation including 
edema formation and leucocyte infiltration through promo-
tion of blood flow. Inhibition by COX enzymes reduces 
edema and suppresses the immunologic response associated 
with inflammation.
Interestingly, in animal models inhibition of COX 
enzymes prior to the onset of sepsis mitigated the physi-
ologic abnormalities seen in sepsis and reduced mortality.23 
In addition, a randomized controlled trial of ibuprofen in 
sepsis demonstrated an improvement in organ dysfunction in 
patients with hypothermia, but did not improve survival.24
Adverse events
It is this enzymatic inhibition of COX-1 and COX-2 that also 
leads to the hematologic, renal, and gastrointestinal adverse 
events associated with NSAIDs.21,22 Other side effects are 
idiosyncratic and less directly related to COX inhibition. 
COX-1 is responsible for the production of thromboxane 
A2, which is expressed in mature platelets. Thromboxane 
A2 acts as a platelet aggregator and enhances the effect of 
other platelet aggregators, including thrombin. While aspirin 
acts as an irreversible inhibitor of COX-1 and thromboxane 
A2 production in a dose-dependent manner, the activity of 
NSAIDs on platelets is temporary and reversible. It is incom-
plete inhibition of platelet aggregation that is believed to lead 
to the increased incidence of thrombotic adverse events with 
NSAIDs, including ibuprofen.21
Within the kidney, COX enzymes synthesize prostaglan-
dins in the medulla and cortex. They play a key role in blood 
pressure regulation and maintenance of renal blood flow, 
especially in patients with long-standing chronic kidney 
disease or who are volume depleted.22 These effects are what 
often lead to the hypertension seen with NSAID therapy. The 
vasodilatory effects of prostaglandins and COX enzymes 
maintain renal blood flow and glomerular filtration, and 
inhibition of their production leads to decreased perfusion 
and a decline in renal function.
Synthesis of PGE2 is cytoprotective within the gastroin-
testinal (GI) tract and is protective against peptic ulcers, even 
without a reduction in acid secretion.21 Inhibition of COX-1 
is thought to be responsible for the increased incidence of 
peptic ulcers and GI bleeding seen with NSAID therapy. 
Ibuprofen is non-selective, and its inhibition of COX-1 and 
COX-2 means that it is prone to GI side effects.
Bronchospasm can also be observed with NSAID therapy 
and is more prevalent in patients with a history of asthma or 
reactive airway disease.21 Inhibition of the COX enzymes 
by NSAIDs shifts metabolism of arachidonic acid from 
PGE2 and PGI2, which relax bronchial smooth muscle.22 
Arachidonic acid instead is synthesized into leukotrienes 
that constrict airway smooth muscle.
Drug interactions
Like oral ibuprofen, the intravenous formulation interacts 
with several medications by either reducing protein binding, 
causing additive side effects, or inhibiting renal prostaglandin 
synthesis. Aspirin, the first and prototypical NSAID, has a 
similar mechanism of action and side effect profile as intra-
venous ibuprofen. When taken concomitantly, the protein 
binding of ibuprofen is reduced while the clearance of free 
ibuprofen is unchanged, although the effect of this interac-
tion is unknown.25 The administration of aspirin or any other 





ibuprofen due to additive COX inhibition and thus additional 
side effects. Concomitant administration of an NSAID with 
anticoagulants including warfarin and heparin products may 
also contribute to additional side effects including the risk 
of gastrointestinal bleeding.25 Patients who frequently use 
dual NSAID therapy have a higher risk of GI bleeding than 
users of either drug alone. In the elderly population, the risk 
of GI bleeding is higher and the interaction of these agents 
could be fatal.
NSAIDS when used in combination with angiotensin con-
verting enzyme (ACE) inhibitors inhibit renal prostaglandin 
synthesis and diminish the antihypertensive effects of these 
agents.25 The inhibition lessens afferent arteriolar flow and 
causes a subsequent decrease in glomerular filtration rate, 
especially in elderly patients. The use of NSAIDS and ACE 
inhibitors in the elderly population has been found to be the 
main cause of drug-induced acute renal failure.26 Sodium 
depletion can also be a precipitating factor in renal failure, 
therefore the use of diuretics and NSAIDS may also lead to 
renal dysfunction.27 Lithium clearance can be decreased by 
20% due to decreased prostaglandin production.25 Multiple 
case reports have documented the relationship between 
acute renal failure and the use of methotrexate and NSAIDS 
simultaneously.28 When using one of these agents concur-
rently with NSAIDS, extra monitoring and vigilance may be 
necessary to prevent lithium and methotrexate toxicity.
Pharmacokinetics
Ibuprofen is a racemic mixture of [-]R- and [+]S-isomers.25 
The [+]S-isomer is responsible for clinical activity   according 
to in vivo and in vitro studies. The [-]R-isomer is slowly 
and incompletely interconverted into the active [+]S-species 
in adults. Active drug levels are maintained by circulating 
reservoir of the [-]R-isomer. As described by early models 
of the oral dosage form, ibuprofen best fits a linear or first-
order pharmacokinetic compartment model. Receipt of 5 to 
10 mg/kg of oral ibuprofen suspension or solution results in 
a time to achieve maximum concentration (tmax) of 0.75 to 
1.5 hours.12,29,30 Elimination half-life is approximately 1.6 
hours. The AUC of plasma ibuprofen is dose-dependent due to 
the concentration-dependent protein binding where doubling 
of the dose (5 to 10 mg/kg) results in a 1.6-fold increase in 
drug exposure.29 Ibuprofen is highly protein bound (.99% 
bound). The protein binding is saturable and at concentrations 
.20 µg/mL becomes nonlinear. The estimated volume of dis-
tribution is 0.11 to 0.21 L/kg based on data from oral ibuprofen 
and there is a known age- and fever-related change.29–32
The terminal half-life of intravenous ibuprofen appears 
to be slightly above 2 hours (mean = 2.26 hours) and consis-
tent across all dosing ranges.25 Similar to data from the oral 
dosage form, antipyretic effects are delayed in relation to 
peak concentrations and last longer despite declining plasma 
ibuprofen concentrations. A summary of the pharmacokinetic 
parameters of intravenous ibuprofen from initial studies are 
detailed in Table 1. Important to note are the differences in 
infusion time among the three studies summarized (5- to 
7-minute rapid infusion, 30-minute infusion, and 60-minute 
infusion).25,33,34 Infusion time greatly influences maximum 
concentration (Cmax) and tmax, which is typically immediately 
following the end of the infusion.
 
Table 1 Summary of pharmacokinetic parameters of intravenous ibuprofen
Parameter  100 mg dose  200 mg dose  400 mg dose  800 mg dose 
Study: Morris et al33
Number of patients  31  30  31  _
AUC (µg.h/mL)  22.33 (12.75)  32.62 (17.39)  70.64 (31.93)  –
Cmax (µg/mL)  12.17 (6.78)  18.93 (10.50)  39.76 (17.75)  –
T1/2 (h)  2.47 (1.15)  2.11 (1.05)  2.26 (0.95)  –
Study: Intravenous ibuprofen product labeling; Data on file with Cumberland Pharmaceuticals® 25,34 
Number of patients  – – 12  12 
AUC (µg.h/mL)  – – 109.3 (26.4)  192.8 (18.5) 
Cmax (µg/mL)  – – 39.2 (15.5) 72.6 (13.2)
T1/2 (h) – – 2.22 (20.1)  2.44 (12.9)
Study: Pavliv et al34 
Number of patients  – – – 12 
AUC (µg.h/mL)  – – – 195.7 (37.3) 
Cmax (µg/mL)  – – – 120.3 (13.5) 
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In a pharmacokinetic study of 24 healthy volunteers, doses 
of 400 mg and 800 mg were administered over 60-minute 
infusions.25 The association between the different doses 
demonstrates a Cmax ratio of 1.7 and an AUC ratio of 1.8 for 
the 400 mg and 800 mg doses, respectively.25 These data are 
similar to the pharmacokinetics observed with oral ibuprofen. 
Unpublished data of a randomized, cross-over, placebo con-
trolled study, examined the pharmacokinetic profile of an 
800-mg dose given via rapid infusion over 5 to 7 minutes.34 
Twelve healthy volunteers, mean age of 31.7 years and 
mean weight of 77 kg, were enrolled. At approximately 
three hours post-dose, the mean serum concentration 
was 20 µg/mL with a half-life of approximately 2 hours. 
The AUCt-inf of 196 µg⋅h/mL (±37) is similar to previous 
pharmacokinetic studies in subjects receiving 800 mg. 
Compared to oral dosing of 800 mg in the same population, 
the AUCs were very similar (196.4 vs 195.7), but Cmax nearly 
doubled (120.3 vs 62.8) with significantly shorter time to 
peak concentrations (6.5 vs 90 minutes).
In a multi-center, randomized, double-blind, placebo-
controlled trial conducted by Morris et al 120 hospitalized 
patients (88 men, 32 women) with temperatures of 38.3°C or 
greater were randomized to intravenous ibuprofen 400 mg, 
200 mg, 100 mg or placebo, administered every 4 hours for 
24 hours over a 30-minute infusion.33 Both first-dose and 
steady state kinetics were evaluated in all 3 dosing arms. Of 
note, 44% of these patients were critically ill and all patients 
were febrile. At all evaluable time points, mean ibuprofen 
concentrations were significantly lower in critically ill 
subjects compared to non-critically ill. Although the influ-
ence of fever specifically within these subgroups cannot be 
evaluated, changes in volume of distribution in a critically ill 
patient may influence the lower Cmax and AUC. For dosing, 
this may implicate the need for higher than 400 mg doses 
in critically ill populations if desired clinical response is not 
achieved. Data regarding the clinical outcomes of this study 
are detailed in later sections. Clinically, 800 mg doses have 
proven effective in a critically ill burn population, however 
the pharmacokinetic profiles have not been reported.35 
Pediatrics
Specific studies of the intravenous ibuprofen formulation 
have not been conducted in pediatrics. Pharmacokinetic 
analyses in febrile children receiving oral ibuprofen demon-
strated obtainment of peak concentrations 0.75 to 1.5 hours 
following oral dosages of 5 to 10 mg/kg.12,29,30,36 Volume 
of distribution was similar to that found in adults, 0.16 to 
0.18 L/kg. Although oral absorption from the   gastrointestinal 
tract was complete, there was a delay in maximum   antipyretic 
effects up to 2.5 hours following achievement of peak 
concentrations.
Age-related phenomena have been well described with 
ibuprofen. Wilson et al demonstrated a difference in anti-
pyretic response in children .6 years of age compared to 
those #6 years old, with no apparent differences in pharma-
cokinetic properties.36 These same investigators also reported 
pharmacokinetic differences in younger children (,2.5 years 
of age) where an increased ibuprofen clearance was observed 
compared to older children, likely due to a larger volume of 
distribution.29
Also, consistent with product labeling of oral ibuprofen 
products, children with a temperature .39.2°C, a dosage 
increase to 10 mg/kg is recommended to compensate for the 
reduced antipyretic effect. Kauffman et al observed a faster 
onset and greater antipyretic effect in children ,1 years of 
age, compared to those .6 years old.12 This was independent 
of any significant differences in pharmacokinetic properties. 
Data using alternative formulations of intravenous ibuprofen 
in special populations of pediatrics are described below 
regarding cerebrospinal fluid (CSF) penetration and use 
in cystic fibrosis patients. Although, there are no current 
recommendations for intravenous ibuprofen in pediatrics, 
the rapid achievement of peak concentrations could prove 
clinically beneficial when timely antipyretic effects are 
desired.
Central nervous system
A single pharmacokinetic study in pediatrics investigated 
the CSF and plasma concentrations of intravenous ibuprofen 
(Ibuprof von ct. Germany) in children following inguinal 
surgery.37 Thirty-six children, aged 3 months to 12 years 
(median 40 months) received a single intravenous injection 
of ibuprofen (10 mg/kg). CSF concentrations ranged between 
15 and 541 µg/L, with the peak concentrations measured 30 
to 38 minutes after dosing. At the onset of post-surgical pain, 
186 to 266 minutes following ibuprofen injection, the corre-
lating plasma concentrations ranged between 10 and 25 mg/L 
(median 21 mg/L). Ibuprofen was over 99% protein bound, 
with a median unbound/total plasma concentrations ratio 
of 0.0020. All ibuprofen CSF concentrations exceeded that 
of unbound plasma concentrations in all samples collected 
30 minutes post-dose. These results suggest a rapid move-
ment of drug into the CSF and sustained plasma analgesic 
concentrations for 2 to 4 hours following a single 10 mg/
kg dose in pediatrics undergoing inguinal surgery. A study 





800 mg oral dose demonstrated a similar peak CSF concentra-
tion, obtained at 3 hours as opposed to 30 minutes following 
intravenous administration.38 In patients undergoing similar 
short-term recovery or outpatient surgeries, this correlates 
well to being able to provide the patient with a second dose 
or discharge dose 3 to 4 hours post surgery.
Penetration into the CSF is governed partially by the lipo-
philicity of the agent. Ibuprofen, similar to other NSAIDS, 
is lipophilic, and thus possesses the ability to readily cross 
the blood–brain and blood–CSF barriers. At physiologic pH 
(7.4), the apparent partition coefficient is 1.1, which sug-
gests ready diffusion into the CSF; however, ibuprofen is 
almost totally ionized at these conditions (99%), restricting 
movement into the CNS.39 The highly protein bound nature 
of ibuprofen may limit its movement across the blood–CSF 
and blood–brain barrier, as only unbound drug can readily 
diffuse. Additional mechanisms have been suggested to 
limit diffusion such as efflux mechanisms at the blood–CSF 
barrier including multidrug resistance proteins and organic 
anion transport systems.40–42 By comparison to ketoprofen 
and indomethacin, ibuprofen seems to more readily cross 
into the CNS, with less interpatient variability.43,44
Cystic fibrosis
As with many drugs, cystic fibrosis (CF) patients appear to 
exhibit altered pharmacokinetics of ibuprofen in comparison 
to healthy controls. The primary pharmacokinetic alterations 
in CF patients include reduced absorption, increased volume 
of distribution, and more rapid clearance.45 The reduction 
in absorption of oral ibuprofen encountered in patients with 
CF leads to a reduction in Cmax and AUC of 27% and 46%, 
respectively, compared to healthy children.46 Although no 
data exist with the intravenous formulation specifically in 
this population, this route of administration may be particu-
larly advantageous in avoiding the interpatient variability 
and reduced absorption encountered with alternative routes 
of administration.
Dosage and administration
The lowest effective dose should be used for the shortest 
duration consistent with individual patient treatment goals. 
The maximum daily dose is 3200 mg.25 Patients should be 
hydrated prior to administration of intravenous ibuprofen 
to reduce the risk of renal adverse reactions. For analgesia, 
400 mg to 800 mg should be administered intravenously every 
6 hours as necessary. For fever 400 mg intravenously fol-
lowed by 400 mg every 4 to 6 hours or 100 to 200 mg every 
4 hours should be administered as necessary. According to the 
product labeling, the minimum infusion time for intravenous 
ibuprofen is 30 minutes. A randomized, cross-over, placebo 
controlled study, examined the safety and tolerability of a 
single 800-mg dose given via rapid infusion over 5 to 7 min-
utes in 12 healthy volunteers, and 4 of 12 subjects reported 
infusion-related site pain.34 Rapid infusion, when tolerated, 
may be pragmatic in the post-operative or intensive care unit 
setting resulting in rapid achievement of Cmax (see Pharma-
cokinetics section), also aiding in administration decisions at 
the patient’s bedside. Intravenous ibuprofen is available as a 
400 mg/4 mL single-dose vial and 800 mg/8 mL single-dose 
vial.25 The stopper in the intravenous ibuprofen vial does not 
contain natural rubber latex, drug natural rubber, or blends 
of natural rubber.
Drug formulation
Ibuprofen, (±)-2-(p-isobutylphenyl) propionic acid, is the 
active ingredient in intravenous ibuprofen (Caldolor®).25 
Arginine is also contained in this product to assist with 
stability at a molar ratio of 0.92:1 of arginine:ibuprofen. 
Ibuprofen is soluble in agents such as acetone and ethanol, 
but only slightly soluble in water (,1 mg/mL). To prevent 
serious phlebitis during administration, the final concentra-
tion during admixture must be 4 mg/mL or less. Intravenous 
ibuprofen is stable when 0.9% sodium chloride injection 
USP (normal saline), 5% dextrose injection USP (D5W), or 
lactated Ringer’s solution is used as the diluent.47 Intravenous 
ibuprofen is available as a 400 mg/4 mL single-dose vial and 
800 mg/8 mL single-dose vial. Once diluted, intravenous 
ibuprofen remains stable for 7 days at room temperature in 
standard lighting.
Clinical evaluation
Results from an increasing number of clinical studies dem-
onstrate an interesting analgesic and antipyretic profile of 
intravenous ibuprofen in the management of mild to moderate 
pain, management of moderate to severe pain as an adjunct 
to opioid analgesics, and reduction of fever. Studies are 
reviewed based on their clinical indication.
Use in post-operative pain
Three randomized, double-blind, placebo-controlled trials 
of intravenous ibuprofen to evaluate the safety and efficacy 
as a post-operative analgesic have been published to date. 
The first examined the effects of intravenously administered 




Review of intravenous ibuprofen
pain management.3 Subjects were recruited through 17 sites 
within the United States, Australia, and the Republic of South 
Africa between February 2005 and September 2006. Subjects 
were scheduled to undergo elective, single-site orthopedic 
or abdominal surgery and were expected to require hospi-
talization and postoperative analgesia with intravenously 
administered morphine for .14 hours after surgery. After 
surgery, all patients received morphine by hospital staff on 
patient request or patient-controlled analgesia (PCA) pump 
(1 to 2 mg every 5 minutes) and were assigned in a 1:1:1 ratio 
using a stratified, blinded by site, randomization scheme to 
receive ibuprofen 400 mg intravenous, ibuprofen 800 mg 
intravenous, or inactive vehicle (placebo), every 6 hours 
for a total of 8 doses, over the first 48 hours of the study. 
After the initial 8 doses, the protocol allowed for continued 
administration of intravenous ibuprofen or placebo every 
6 hours, at the discretion of the investigator, for control of 
postoperative pain for a total of up to 120 hours (5 days). The 
primary outcome measure was the mean amount of morphine 
administered during the first 24 hours following surgery. Sta-
tistical analyses of the efficacy end points were conducted on 
the intent-to-treat (ITT) population and the efficacy-evaluable 
(EE) population (all patients who received at least 4 doses of 
intravenous ibuprofen or placebo within 60 minutes of the 
scheduled administration time). A total of 406 patients were 
enrolled and were all included in the ITT population, and a 
total of 342 patients who received the first 4 doses of study 
medication were included in the EE population. In the ITT 
population, median morphine use was significantly reduced 
during the first 24 hours of administration of study drug in 
patients who received ibuprofen 800 mg intravenous every 
6 hours by 22% vs placebo (P = 0.030); the difference in 
morphine use between the ibuprofen 400 mg intravenous 
and placebo groups was not significant.
In a second multi-center, randomized, double-blind, 
  placebo-controlled trial, women who had undergone an elec-
tive abdominal hysterectomy, were randomized and treated 
with intravenous ibuprofen 800 mg or placebo administered 
every 6 hours started intra-operatively.48,49 Subjects also 
received morphine administered on an as needed basis. Effi-
cacy was demonstrated by measuring the patients’ morphine 
usage during the post-operative period and self assessment of 
pain at rest and with movement using a visual analog scale 
(VAS). The study found that patients receiving 800 mg of 
intravenous ibuprofen had 19% less median morphine use. 
Subjects receiving intravenous ibuprofen had a 21% and 
14% reduction in pain intensity on the VAS at rest and with 
movement, respectively. The median morphine usage is sum-
marized in Table 2.
In a third multi-center, randomized, double-blind, 
  placebo-controlled trial, a total of 185 patients undergo-
ing elective knee or hip orthopedic surgery were randomly 
assigned in 1:1 ratio to receive either 800 mg intravenous 
ibuprofen or placebo every 6 hours.50 In addition, all patients 
had access to morphine, and the first dose of study medication 
was administered prior to surgery. Efficacy was demonstrated 
by measuring the patients’ self-assessment of pain with 
movement and at rest using a VAS and a verbal response 
scale (VRS). Morphine use during the post-operative period 
was also compared between groups as an efficacy measure. 
Patients receiving 800 mg intravenous ibuprofen compared 
to placebo experienced a significant reduction in pain as mea-
sured by the area under the curve of the VAS (VAS-AUC) 
with movement and at rest for the post-operative period, study 
hours 6 to 28 (P , 0.001). There was a 25.8% reduction in 
mean VAS-AUC (with movement) (P , 0.001) and a 30.9% 
reduction in morphine usage (P , 0.001) in patients receiv-
ing intravenous ibuprofen. There was a 31.8% reduction in 
mean VAS-AUC (at rest) and a 20.2% reduction in mean 
VRS in patients receiving intravenous ibuprofen. There was 
not a significant difference in the number of adverse events 
observed between the treatment groups.
Use for fever
Morris et al investigated intravenous ibuprofen to reduce 
fever.33 One hundred twenty hospitalized adult patients at 
nine sites (88 men, 32 women) with temperatures of 38.3°C 
or greater were randomized to intravenous ibuprofen 400 mg, 
200 mg, 100 mg or placebo, administered every 4 hours for 
24 hours. Fifty-three of the 120 patients (44%) were critically 
ill and receiving mechanical ventilation and/or vasopressor 
support. The primary objective was to evaluate the efficacy 
of 400 mg intravenous ibuprofen on reducing fever to greater 
than or equal to 38.3°C, determined by the percentage of 
subjects with temperature less than 38.3°C at 4 hours after 
administration of a single dose, as compared with the efficacy 
of parallel placebo treatment. Each of the three intravenous 
ibuprofen doses, 100 mg, 200 mg, and 400 mg, resulted in a 
statistically greater percentage of patients with a reduced tem-
perature (,3) after 4 hours, compared to placebo (61%, 70%, 
77% and 32%, respectively). Temperature decreased in both 
the critically ill and non-critically ill subjects receiving intra-
venous ibuprofen versus those receiving placebo. However, 





Table 2 Summary of intravenous ibuprofen clinical studies
Author Study aim Treatment arm Results
Kroll et al49 Efficacy and safety in adult  
abdominal surgery patients  
(N = 319) 
800 mg IV or placebo every  
6 hours + PRN morphine
Efficacy: morphine requirements in  
ibuprofen group 43.7 mg and placebo 
56 mg (P , 0.001) 




Efficacy (fever and pain) and  
safety in pediatric and adult burn  
patients (N = 61)
800 mg IV or placebo every 
6 hours during 120-hour 
treatment period
Efficacy: significant reduction in fever in  
800 mg ibuprofen versus placebo in first 
24 hours as measured by AUC-T (P = 0.03) 
Safety: no significant difference between  
the two groups for adverse events; no  
differences between the groups for  
laboratory values, frequency of blood  
transfusions, or bleeding
Morris et al33 Efficacy (fever) and safety in  
hospitalized adult patients  
(N = 120; ∼33% were critically illa)
100 mg, 200 mg, 400 mg IV  
or placebo every 4 hours  
for a total of 6 doses
Efficacy: proportion of patients ,38.3°C 
at 4 hours post initial dose: placebo 
(32%), 100 mg (61%), 200 mg (70%), 
400 mg (77%) (P , 0.05 for all 
treatment arms versus placebo) 
Safety: no statistical significant differences 
in serious adverse events between 




Efficacy and safety in hospitalized  
adult orthopedic surgery patients 
(N = 185)
800 mg IV or placebo every  
6 hours + PRN morphine
Efficacy: morphine requirements 
reduced by 30.9% compared to placebo 
(P , 0.001); reduction of 20%–32% 
in mean VAS-AUC (at movement 
and rest) and VRS; 
Safety: significant increase in vomiting in 
the treatment arm versus placebo
Southworth et al3 Efficacy and safety in adult  
abdominal (73%) or orthopedic  
surgery patients (27%) (N = 406)
400 mg, 800 mg IV or  
placebo every 6 hours for  
8 doses + morphine PCA
Efficacy: morphine requirements reduced 
by 22% in the 800 mg arm (P = 0.03), 
3% in the 400 mg arm (P = NS) versus 
placebo; 800 mg arm resulted in significant 
reductions in pain earlier than 400 mg arm 
when compared to placebo (1–6 hours 
versus 6–12 hours) 
Safety: no significant differences in serious   
adverse events between treatment arms  
through study day 14
aCritically ill defined as mechanical ventilation and/or requiring vasopressor support. 
Abbreviations: IV, intravenous; PRN, as needed; AUC-T, area under the temperature curve; VAS, visual analog scale; VRS, verbal response scale; PCA, patient-controlled 
analgesia.
between treatment doses. This study may   demonstrate that 
higher doses, such as 800 mg are required for fever reduction 
in critically ill patients.
The antipyretic effects have also been demonstrated in 
a critically ill burn population.35,51 Patients in this random-
ized, double-blind, placebo-controlled trial were enrolled 
from 5 burn centers or units both domestic and international. 
A total of 61 adult patients with second- or third-degree burns 
over at least 10% body surface area were included. Patients 
received either placebo or 800 mg intravenous ibuprofen 
every 6 hours for 5 consecutive days. Significant reductions 
in fever curve were noted in the first 24 hours.
Use in arrhythmias
Threatening arrhythmias were suppressed following the 
  administration of intravenous ibuprofen during electrical storm.52 
In 4 patients admitted with a diagnosis of cardiomyopathy and 
atrioventricular block secondary to an acute ischemic insult, life-
threatening ventricular tachyarrhythmias responded to a single 
intravenous 400 mg dose of ibuprofen. In each case, the arrhyth-
mias were refractory to amiodarone treatment. This is the first 
report of suppression of arrhythmias through the administration 
of an anti-inflammatory medication. Although, this provides 
some evidence for ibuprofen in arrhythmias, more data on its 
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Use in pediatrics
Currently the use as an analgesic in pediatrics is limited to 
a pharmacokinetic study not designed to evaluate efficacy.37 
As described above, 36 children received a single 10 mg/kg 
dose of intravenous ibuprofen over 5-minute rapid infusion 
prior to surgery using spinal anesthesia. Additionally, most 
children were premedicated with midazolam and ketamine 
prior to receiving bupivicaine for spinal anesthesia. The 
median time to pain after surgery was 138 minutes (range 57 
to 231   minutes) and after ibuprofen injection was 213 minutes 
(range of 186 to 266 minutes). Three children received a sec-
ond dose of ibuprofen in the post-anesthesia care unit, while 
25 received ketoprofen. Ten children reported severe pain 
defined as .3/10 at rest or .5/10 with 20-N compression post 
surgery that required opioid rescue. Data using intravenous 
ibuprofen in burn patients included pediatric and adult patients. 
However, pediatric specific data are not available.35
Additional data in pediatrics focuses on infantile use in 
patent ductus arteriosus with alternative intravenous ibupro-
fen products. These data are not reviewed here.53–55
Safety and tolerability
Post-operative patients
Southworth and colleagues determined that 91% (368/406) 
of patients experienced treatment-emergent adverse events 
when comparing morphine PCA combined with 400 mg 
or 800 mg of intravenous ibuprofen or placebo.3 Nausea, 
vomiting, and constipation occurred most frequently in 
all study arms including placebo with fewer side effects 
observed with ibuprofen. There was significantly less nausea 
with 400 mg ibuprofen relative to placebo. This apparent 
reduction in gastrointestinal side effects is likely related to 
a reduction in opioid use and a corresponding reduction in 
their adverse effects. Pyrexia was also significantly reduced 
in the 400 mg and 800 mg ibuprofen arms as compared to 
placebo. In the 800 mg ibuprofen arm, a statistical reduc-
tion was found in the incidence of dizziness as compared 
to placebo. Laboratory values including renal function and 
vital sign measurements were similar throughout the study 
in all three groups. The incidence of bleeding and bruising 
did not differ significantly between the groups. Overall, the 
total blood units transfused during the study were similar 
amongst all three arms. Of the 406 patients treated in this 
study, there were no deaths reported. Discontinuation of 
the study drug occurred on day 5 of 14 for all 406 patients. 
Most of these patients were able to tolerate oral pain medi-
cation on day 5, and therefore the intravenous therapy was 
discontinued.
In 319 female patients undergoing elective abdominal 
hysterectomy, randomized to receive 800 mg intravenous 
ibuprofen every 6 hours or placebo, there were no differences 
in treatment-emergent adverse events.48,49 Clinical laboratory 
assessments including renal and hepatic function were similar 
between the two groups and the most common side effects 
were similar to those associated with oral ibuprofen use. 
Serious adverse effects were determined to be related to the 
hysterectomy procedure itself, and not study drug. Similar 
results were found in the 185 patients undergoing orthopedic 
elective knee or hip surgery, with the exception of a difference 
in gastrointestinal side effects. There were significantly more 
patients who experienced emesis in the ibuprofen group as 
compared to placebo, however significantly more patients in 
the placebo group reported dyspepsia.
A study of hospitalized burn patients found no signifi-
cant differences between the group treated with intravenous 
ibuprofen 800 mg and placebo.51,56 No significant differences 
in the incidences leucocytosis and anemia were found. Five 
subjects experienced 6 serious adverse events in the ibuprofen 
group and 3 subjects experienced 6 adverse events in the pla-
cebo group. There was no difference in the clinical laboratory 
assessments (serum creatinine levels, hemoglobin, platelet 
counts, prothrombin time, or activated partial thromboplas-
tin time) between the two groups. The frequency of blood 
transfusions was similar in both groups. Findings from this 
study were similar to previous studies and demonstrated a 
relatively favorable side effect profile.
Critically ill patients
Morris and colleagues evaluated the safety and efficacy 
of intravenous ibuprofen in 120 hospitalized adult febrile 
patients.33 Between the 100 mg, 200 mg, and 400 mg arms of 
intravenous ibuprofen as compared to placebo, there were no 
statistically significant differences when comparing the three 
groups except for the incidence of bacteremia. In the 100 mg 
intravenous ibuprofen group, there were 4 cases of bacteremia 
(13%) as compared to 0% in the placebo group. Since this 
increase was not observed in any other ibuprofen arms, it is 
unlikely that these events were associated with the study drug 
as this side effect. Like the previous studies, there were no 
differences found between the three groups in terms of seri-
ous adverse events, bleeding or bruising, laboratory values, 
hemoglobin/hematocrit values, or transfusion requirements.
Bleeding
One of the major concerns in using intravenous ibuprofen 





prospective, phase III, randomized, placebo-controlled, 
double-blind study that enrolled 450 patients with severe 
sepsis syndrome, intravenous ibuprofen was administered to 
determine the efficacy and safety of intravenous ibuprofen in 
reducing mortality.23 Patients received 10 mg/kg of intrave-
nous ibuprofen every 6 hours times 8 doses for a maximum 
infusion of 6400 mg intravenous or placebo after diagnosis 
of sepsis syndrome. Evaluation of bleeding events, tranfu-
sion requirements, and serial laboratory measurements were 
documented (hemoglobin, hematocrit, platelets, pro-thrombin 
time, and activated partial thromboplastin time) at baseline 
and 0, 20, 44, 72, 96, and 120 hours after initiation of therapy. 
There were 15 events in the ibuprofen arm and 25 events in 
the placebo arm that could be classified as bleeding com-
plications Of the 40 total bleeding events, the majority of 
these were related to gastrointestinal bleeding (19 placebo, 
9 ibuprofen). Two patients in the placebo arm experienced a 
cerebrovascular accident compared to 3 patients in the ibu-
profen arm. One patient in the ibuprofen arm experienced a 
pulmonary hemorrhage. At baseline, 117 patients received 
transfusions with an additional 146 in the placebo group and 
153 in the ibuprofen group receiving transfusions at the onset 
of dosing through 120 hours. Administration of total blood 
products including packed red blood cells, platelets, fresh 
frozen plasma and albumin were similar between the two 
groups. In the ibuprofen group, the average units transfused 
per patient was 3.66 ± 0.33 units versus 3.34 ± 0.26 units in the 
placebo group. Of the laboratory values assessed for bleeding, 
no statistical differences between the groups were observed 
at any time point (P . 0.05). Overall, patients treated with 
intravenous ibuprofen in the setting of sepsis syndrome where 
the bleeding risk is extremely high, there were no differences 
in bleeding events, transfusion requirements, or coagulation 
abnormalities.
Infusion-related reactions
According to the package insert, intravenous ibuprofen infu-
sion time should be no less than 30 minutes due to concerns 
of infusion related reactions.25 In a pharmacokinetics study 
conducted by Pavliv, 12 healthy patients were administered 
800 mg of intravenous ibuprofen over 5 to 7 minutes + oral 
placebo followed by a 7-day washout period when they 
received 800 mg of   ibuprofen + placebo intravenous ibuprofen 
over 5 to 7 minutes.34 The objective of this study was to evalu-
ate the pharmacokinetic profile and safety and tolerability 
of administering rapid infusion intravenous ibuprofen. The 
intravenous ibuprofen formulation was considered equivalent 
to the oral therapy. More importantly, minor infusion related 
reactions were   documented. Four patients experienced pain 
upon infusion while no patients experienced burning while 
receiving intravenous ibuprofen. All four of the adverse events 
resolved and no subsequent changes in vital signs were noted. 
Therefore, intravenous ibuprofen may be administered safety 
over 5 to 7 minutes if needed with minimal infusion related 
adverse effects.
Invasive group A streptococcal infections
The use of NSAIDS has been associated with invasive group 
A beta-hemolytic streptococcal infections including necrotiz-
ing skin and soft tissue infections.57–59 Associations have been 
strongest in pediatric patients and those with a previous vari-
cella infection.60,61 Determination of a true causal relationship 
is difficult for several reasons including the ubiquitous use of 
NSAIDs, inherent limitations of the retrospective study design, 
and overall relatively low incidence of necrotizing GAS 
infections. NSAID therapy may delay diagnosis of invasive 
infections when used for antipyretic and analgesic effects early 
in the disease process.57–59 Alternatively, COX inhibition may 
blunt the immune response and decrease leukocyte activity and 
endothelial interactions at the site of infection.62,63
Bone effects
Several studies have proven that nonspecific NSAIDS may 
inhibit new bone growth and interrupt fracture healing.64,65 
Recently, Goodman and colleagues conducted a study in 
rabbits comparing a non-specific COX-1 and COX-2 inhibi-
tor, and a specific COX-2 inhibitor to determine differences 
in bone ingrowth and tissue differentiation.66 By using a 
titanium implant, or harvest chamber, researchers were able 
to monitor new bone growth in New Zealand white rabbits 
after administration of NSAIDS. The researchers found 
that when administered naproxen (non-specific COX-1 and 
COX-2 inhibitor), tissue bone ingrowth decreased by 15.9% 
versus 18.5% with the rofecoxib (selective COX-2 inhibitor). 
Although these results were not statistically significant, the 
authors concluded that bone ingrowth or fracture healing may 
be delayed when agents with COX-2 inhibitory properties are 
used. Because the bone healing of rabbit is very similar to 
humans, these data can be applicable. The authors concluded 
that patients should not take COX-2 inhibitors for at least 
6 weeks following a fracture or implant procedure, although 
the duration of effect is still currently under research.
Summary of safety and tolerability
Overall data indicate a similar safety and tolerability profile 
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Cardiovascular thrombotic events, gastrointestinal 
effects, bleeding, hypertension, renal effects, anaphylactoid 
reactions, and bronchospasm have all been observed with 
oral ibuprofen therapy. Many of these side effects were not 
observed in studies of intravenous ibuprofen, but are still pos-
sible. The short study durations and inclusion of patients with 
few co morbidities reduced the likelihood of these adverse 
events during studies of intravenous ibuprofen. In addition, 
the longer duration of oral ibuprofen therapy is a likely con-
tributor to the cardiovascular thrombotic effects, bleeding 
events, and renal effects. The potential for cardiovascular 
thrombotic events make ibuprofen a less desirable option for 
post-operative pain secondary to cardiac or vascular surgery 
procedures. In addition, although no adverse effects on renal 
function were observed in trials of intravenous ibuprofen 
it should be used with caution in patients with underlying 
renal disease. Patients with a history of bleeding also may 
be poor candidates for therapy with intravenous ibuprofen, 
and patients with a history of GI bleeding should not receive 
intravenous ibuprofen. These patients were excluded from 
clinical trials and an increased risk of bleeding was not 
observed. However, the GI side effects from ibuprofen arise 
from both topical injury and COX-1 inhibition, which is 
present even when a parenteral formulation is used.67 For 
reasons detailed above, although most of these side effects 
are not experienced in trials of intravenous ibuprofen, the 
manufacturer still details these precautions for the intrave-
nous formulation.
Summary and recommendations
Intravenous ibuprofen is an attractive option for the treat-
ment of pain in the acute post-operative setting and for use 
in the critically ill population. Data in a relatively small 
number of patients demonstrate its efficacy in reducing 
opioid requirements and pain scores relative to placebo in 
a variety of post-operative settings including abdominal 
and orthopedic procedures. In addition, data support its 
efficacy in reducing fever in the acute and critical care 
settings. Doses of 400 to 800 mg are recommended for 
both analgesic and antipyretic effects in these settings. 
In the critically ill population, higher single doses of 800 
mg should be considered to maximize desired effects. 
Although a 30-minute infusion is recommended, data on 
the safe use of a rapid infusion of 5 to 7 minutes are encour-
aging for ease of administration and optimizing rapid 
onset. Recognition of injection site pain with intravenous 
administration is important, specifically when employing 
a rapid infusion.
Although chronic or long-term therapy is not likely with 
the intravenous dosage form, extended use in the hospitalized 
patient should be anticipated. Extra caution and monitoring 
are required in patients for extended use and those with sig-
nificant co-morbidities, including those undergoing cardiac 
or vascular procedures. Post-marketing surveillance will be 
critical as intravenous ibuprofen becomes more widely used. 
Current studies include relatively small numbers of patients, 
making differences in adverse events difficult to detect. They 
also followed patients for relatively short periods of time, 
and toxicities are more likely to be seen with prolonged 
therapy.67 At this time, intravenous ibuprofen appears to be 
a useful adjunct for short-term use in post-operative pain 
in adult patients without significant underlying disease 
states and for potential use in critically ill patients for desired 
antipyresis.
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